Esanex Inc

Esanex Has Successful Ph II Meeting with FDA Meeting for SNX-5422 Upcoming Trial in Neuroendocrine Tumors
CP Wire
Thu, 10/4/18 - 09:44 am
Esanex Inc
SNX-5422
neuroendocrine tumors
Esanex Has Successful Ph II Meeting with FDA Meeting for SNX-5422 Upcoming Trial in Neuroendocrine Tumors
Thu, 10/4/18 - 09:28 am
Esanex Inc
SNX-5422
neuroendocrine tumors
Pharma startup led by Lilly Ventures execs raises $4.6 million
MedCity News
Sat, 05/5/12 - 02:11 pm
Esanex Inc
Lilly Ventures